News
-
-
Kriya Selected for FDA PreCheck Pilot Program
-
Kriya Announces Presentations at ASGCT 2026 Highlighting Advances Across Gene Therapy Platform
-
Kriya Appoints Sachiyo Minegishi as Chief Financial Officer
-
Kriya appoints Greg Di Russo, MD as Chief Medical Officer
-
Kriya Announces $320 Million Series D Financing to Advance Pipeline of Gene Therapies for Chronic Diseases of High Unmet Need
-
Kriya Presents Data at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
-
Kriya Announces Thirteen Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2025
-
Kriya Announces Publication of Preclinical Data for its Investigational AAV-FGF21 Gene Therapy Demonstrating Durable Reversal of Liver Fibrosis
-
Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene Therapy Product Candidate for Thyroid Eye Disease (TED), at ESOPRS Annual Meeting